The weight loss drugmaker Novo Nordisk is trying to shore up its obesity pipeline with a potential alternative to its blockbuster Wegovy, but early data the company presented on Tuesday don’t look too ...
We are increasing our fair value estimate for Eli Lilly LLY to $500 per share from $450 following the firm’s solid fourth-quarter results, featuring robust sales from diabetes drug Mounjaro and strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results